2018
A Role for Hypocretin/Orexin in Metabolic and Sleep Abnormalities in a Mouse Model of Non-metastatic Breast Cancer
Borniger J, Walker W, Surbhi, Emmer K, Zhang N, Zalenski A, Muscarella S, Fitzgerald J, Smith A, Braam C, TinKai T, Magalang U, Lustberg M, Nelson R, DeVries A. A Role for Hypocretin/Orexin in Metabolic and Sleep Abnormalities in a Mouse Model of Non-metastatic Breast Cancer. Cell Metabolism 2018, 28: 118-129.e5. PMID: 29805100, PMCID: PMC6031468, DOI: 10.1016/j.cmet.2018.04.021.Peer-Reviewed Original ResearchConceptsTumor-bearing miceSleep abnormalitiesMetabolic abnormalitiesIL-6Non-metastatic breast cancerHypocretin/orexin neuronsHypothalamic hypocretin/orexin neuronsPeripheral sympathetic denervationSerum leptin concentrationsTumor-induced increaseTumor-induced changesEnhanced sleep qualityHypocretin/orexinPeripheral inflammationSympathetic denervationExogenous ghrelinOrexin neuronsLeptin concentrationsInterleukin-6Serum glucoseMammary cancerBreast cancerSleep qualityMouse modelCentral neuromodulatorsOATP1B2 deficiency protects against paclitaxel-induced neurotoxicity
Leblanc A, Sprowl J, Alberti P, Chiorazzi A, Arnold W, Gibson A, Hong K, Pioso M, Chen M, Huang K, Chodisetty V, Costa O, Florea T, de Bruijn P, Mathijssen R, Reinbolt R, Lustberg M, Sucheston-Campbell L, Cavaletti G, Sparreboom A, Hu S. OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity. Journal Of Clinical Investigation 2018, 128: 816-825. PMID: 29337310, PMCID: PMC5785270, DOI: 10.1172/jci96160.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBiomarkersCell Line, TumorGenotypeHEK293 CellsHumansHyperalgesiaInhibitory Concentration 50Liver-Specific Organic Anion Transporter 1MCF-7 CellsMiceMice, Inbred DBAMice, KnockoutMice, TransgenicOrganic Anion TransportersPaclitaxelPeripheral Nervous System DiseasesPhenotypePyrimidinesConceptsPaclitaxel-induced neurotoxicityDose-limiting peripheral neurotoxicityTyrosine kinase inhibitor nilotinibAction potential amplitudeKinase inhibitor nilotinibPeripheral neurotoxicityThermal hyperalgesiaTherapeutic managementPotential amplitudeNeurotoxicityAnticancer propertiesNoncompetitive mechanismAnticancer drugsPaclitaxelAllodyniaHyperalgesiaPotential implicationsNilotinibOatp1b2Mice
2017
Multispectral Imaging Analysis of Circulating Tumor Cells in Negatively Enriched Peripheral Blood Samples
Miller B, Lustberg M, Summers T, Chalmers J. Multispectral Imaging Analysis of Circulating Tumor Cells in Negatively Enriched Peripheral Blood Samples. Methods In Molecular Biology 2017, 1634: 219-234. PMID: 28819855, DOI: 10.1007/978-1-4939-7144-2_19.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBreast NeoplasmsCarbocyaninesCell CountCell Line, TumorEpithelial Cell Adhesion MoleculeFemaleFluorescent DyesHumansHydrazinesImage Processing, Computer-AssistedIndolesKeratinsLeukocyte Common AntigensLeukocytes, MononuclearLiquid CrystalsNeoplastic Cells, CirculatingOptical ImagingSoftwareSuccinimidesConceptsPeripheral blood samplesBlood samplesPeripheral bloodTumor cellsLiquid biopsyUseful predictive markerSolid tumor malignanciesVariety of disordersUndefined cell typesLow EpCAM expressionSpecific cell surface markersCell surface markersVariety of biomarkersPredictive markerTherapeutic responseSolid tumorsPositive selection technologyDisease statusTumor malignancyFuture validation studiesEpCAM expressionSurface markersMultispectral imaging analysisProtein levelsExact role
2016
Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer
Himmel L, Lustberg M, DeVries A, Poi M, Chen C, Kulp S. Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer. Experimental And Toxicologic Pathology 2016, 68: 505-515. PMID: 27555377, PMCID: PMC5203928, DOI: 10.1016/j.etp.2016.08.001.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic Combined Chemotherapy ProtocolsApoptosisBlotting, WesternCell Line, TumorCell SurvivalCognition DisordersCyclophosphamideDNA DamageDoxorubicinFemaleHumansImmunohistochemistryMiceMice, NudeMinocyclineNeuroprotective AgentsTriple Negative Breast NeoplasmsXenograft Model Antitumor AssaysConceptsTriple-negative breast cancerChemotherapy-induced cognitive impairmentBreast cancer patientsNeural progenitor cellsPutative neuroprotectantCancer patientsBreast cancerXenograft modelDoublecortin-positive neural progenitor cellsFemale athymic nude miceDoxorubicin-cyclophosphamide chemotherapyProgenitor cellsEffects of minocyclineChemotherapeutic drug combinationsOrgan weight measurementsAbsence of minocyclineAthymic nude miceTNBC cell linesTumor-bearing miceAnti-oxidant pathwaysTumor-suppressive effectsBiomarkers of apoptosisTumor volume measurementsHuman neurologic diseasesMechanism of action
2014
CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth
Mathsyaraja H, Thies K, Taffany D, Deighan C, Liu T, Yu L, Fernandez S, Shapiro C, Otero J, Timmers C, Lustberg M, Chalmers J, Leone G, Ostrowski M. CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth. Oncogene 2014, 34: 3651-3661. PMID: 25241894, PMCID: PMC4369473, DOI: 10.1038/onc.2014.294.Peer-Reviewed Original ResearchConceptsTumor-infiltrating myeloid cellsMetastatic tumor growthMyeloid cellsMiR-21Breast cancerTumor growthHuman metastatic breast cancerMetastatic tumor burdenMetastatic breast cancerPro-tumor functionsAnti-angiogenic genesAttractive therapeutic targetTumor cell proliferationPro-angiogenic propertiesMature myeloid cellsTumor burdenMonocytes correlatesPoor prognosisMelanoma metastasesMouse modelTherapeutic targetSolid tumorsOncogenic roleSurvival rateTherapeutic efficacyHeterogeneous atypical cell populations are present in blood of metastatic breast cancer patients
Lustberg M, Balasubramanian P, Miller B, Garcia-Villa A, Deighan C, Wu Y, Carothers S, Berger M, Ramaswamy B, Macrae E, Wesolowski R, Layman R, Mrozek E, Pan X, Summers T, Shapiro C, Chalmers J. Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients. Breast Cancer Research 2014, 16: r23. PMID: 24602188, PMCID: PMC4053256, DOI: 10.1186/bcr3622.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntigens, CDAntigens, Differentiation, MyelomonocyticAntigens, NeoplasmBiomarkers, TumorBreast NeoplasmsCell Adhesion MoleculesCell Line, TumorEpithelial Cell Adhesion MoleculeErbB ReceptorsFemaleFlow CytometryHumansImmunohistochemistryKeratin-18Keratin-19Keratin-8Leukocyte Common AntigensMCF-7 CellsMicroscopy, ConfocalMiddle AgedNeoplasm MetastasisNeoplastic Cells, CirculatingPrognosisProspective StudiesVimentinConceptsMetastatic breast cancerBreast cancer patientsBlood samplesCancer patientsBreast cancerMetastatic breast cancer patientsPatient samplesMultiparametric flow cytometry analysisAtypical cell populationNumber of CKPresent prospective trialWorse overall survivalTumor-associated macrophagesCell populationsPan-hematopoietic marker CD45Confocal microscopyEpidermal growth factor receptorEpithelial cell adhesion moleculeNormal control samplesCell surface markersRole of EpCAMFlow cytometry analysisGrowth factor receptorOverall survivalProspective trial
2013
Isolation and analysis of rare cells in the blood of cancer patients using a negative depletion methodology
Wu Y, Deighan C, Miller B, Balasubramanian P, Lustberg M, Zborowski M, Chalmers J. Isolation and analysis of rare cells in the blood of cancer patients using a negative depletion methodology. Methods 2013, 64: 169-182. PMID: 24056212, PMCID: PMC3874448, DOI: 10.1016/j.ymeth.2013.09.006.Peer-Reviewed Original ResearchConceptsCancer patientsMetastatic breast cancer patientsBreast cancer patientsPeripheral blood samplesRed blood cell lysisRare cellsNon-hematopoietic cellsBlood cell lysisImmunomagnetic depletionCD45 antibodyBlood samplesLog depletionPatientsImmunofluorescence stainingNucleated cellsWhole bloodBloodCD45RBC lysisCellsCell lysisLysisAntibodies
2012
Multiparameter Analysis, including EMT Markers, on Negatively Enriched Blood Samples from Patients with Squamous Cell Carcinoma of the Head and Neck
Balasubramanian P, Lang J, Jatana K, Miller B, Ozer E, Old M, Schuller D, Agrawal A, Teknos T, Summers T, Lustberg M, Zborowski M, Chalmers J. Multiparameter Analysis, including EMT Markers, on Negatively Enriched Blood Samples from Patients with Squamous Cell Carcinoma of the Head and Neck. PLOS ONE 2012, 7: e42048. PMID: 22844540, PMCID: PMC3406036, DOI: 10.1371/journal.pone.0042048.Peer-Reviewed Original ResearchConceptsEpithelial surface markersN-cadherinEpidermal growth factor receptorGrowth factor receptorSurface markersPositive selection approachEpithelial markersAforementioned proteinsMesenchymal transitionFactor receptorConfocal microscopyCancer metastasisEMT processCancer cellsPhenotypic patternsMesenchymal markersTumor metastasisEnrichment methodologyEMT markersEnrichment technologyCellsEMTExpressionTumor cellsMarkers